Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Yee

Showing results (171-180 of 188) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug developmentDouglas Yee, Tufia Haddad, Kathy Albain, et al.
Annals of Surgical Oncology|August 23, 2025
ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical TrialRita A Mukhtar, Katrina Dimitroff, Christina Yau, et al.
Annals of Surgical Oncology|July 23, 2025
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 TrialMandeep Kaur, Katrina Dimitroff, Judy C Boughey, et al.
JAMA Network Open|December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast CancerBeverly Kyalwazi, Christina Yau, Michael J Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Neratinib in Early Breast CancerJohn W Park, Minetta C Liu, Douglas Yee, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast CancerHope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, et al.
JAMA Oncology|December 18, 2025
Enhancing Clinical Cancer Research Through Sharing of Data and BiospecimensHans Wildiers, Virginie Adam, Seamus O'Reilly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 TrialA Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Pageof 19

Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug developmentDouglas Yee, Tufia Haddad, Kathy Albain, et al.
Annals of Surgical Oncology|August 23, 2025
ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical TrialRita A Mukhtar, Katrina Dimitroff, Christina Yau, et al.
Annals of Surgical Oncology|July 23, 2025
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 TrialMandeep Kaur, Katrina Dimitroff, Judy C Boughey, et al.
JAMA Network Open|December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast CancerBeverly Kyalwazi, Christina Yau, Michael J Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Neratinib in Early Breast CancerJohn W Park, Minetta C Liu, Douglas Yee, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast CancerHope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, et al.
JAMA Oncology|December 18, 2025
Enhancing Clinical Cancer Research Through Sharing of Data and BiospecimensHans Wildiers, Virginie Adam, Seamus O'Reilly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 TrialA Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Pageof 19